Amar Duvvur is Capsida’s chief operating officer and chief financial officer. He has more than 25 years of finance leadership experience across biotech, pharmaceuticals, medical devices, and diversified industrials.
Beth Seidenberg, M.D., is a longtime life sciences investor, applying her broad medical expertise to the venture capital world, where she assists entrepreneurs in translating their scientific breakthroughs into new medicines to help patients.
Mina Kim is Capsida’s executive chair of the board. She has more than 20 years of operational and leadership experience and previously held executive roles at Acelyrin and Zymergen.
Nicholas Flytzanis co-founded Capsida Biotherapeutics and is its chief scientific officer. Nicholas Flytzanis previously served as scientific director of the CLOVER research center at the California Institute of Technology (Caltech).
Capsida’s privacy policy describes how it handles personal data and states that using or accessing its site constitutes consent to its practices and policies.
